© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Calidi Biotherapeutics, Inc. (CLDI) stock declined over -1.61%, trading at $1.22 on AMEX, down from the previous close of $1.24. The stock opened at $1.27, fluctuating between $1.21 and $1.27 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 14, 2026 | 1.27 | 1.27 | 1.21 | 1.22 | 17.49K |
| Sep 11, 2026 | 1.24 | 1.28 | 1.22 | 1.24 | 70.63K |
| Sep 10, 2026 | 1.31 | 1.34 | 1.30 | 1.31 | 32.35K |
| Sep 09, 2026 | 1.33 | 1.37 | 1.30 | 1.36 | 45.31K |
| Sep 08, 2026 | 1.38 | 1.40 | 1.25 | 1.35 | 29.98K |
| Sep 04, 2026 | 1.38 | 1.40 | 1.35 | 1.39 | 19K |
| Sep 03, 2026 | 1.33 | 1.38 | 1.32 | 1.35 | 23.58K |
| Sep 02, 2026 | 1.33 | 1.41 | 1.33 | 1.34 | 30.13K |
| Sep 01, 2026 | 1.33 | 1.36 | 1.28 | 1.33 | 48.51K |
| Aug 31, 2026 | 1.32 | 1.38 | 1.31 | 1.34 | 35.83K |
| Aug 28, 2026 | 1.32 | 1.37 | 1.28 | 1.32 | 51.8K |
| Aug 27, 2026 | 1.33 | 1.42 | 1.26 | 1.30 | 129.42K |
| Aug 26, 2026 | 1.31 | 1.37 | 1.31 | 1.35 | 39K |
| Aug 25, 2026 | 1.35 | 1.41 | 1.31 | 1.31 | 48.23K |
| Aug 24, 2026 | 1.34 | 1.38 | 1.26 | 1.38 | 62.15K |
| Aug 21, 2026 | 1.35 | 1.41 | 1.31 | 1.34 | 58.15K |
| Aug 20, 2026 | 1.35 | 1.39 | 1.27 | 1.34 | 77.65K |
| Aug 19, 2026 | 1.25 | 1.46 | 1.25 | 1.38 | 136.77K |
| Aug 18, 2026 | 1.32 | 1.34 | 1.25 | 1.30 | 128.94K |
| Aug 17, 2026 | 1.58 | 1.58 | 1.33 | 1.36 | 295.38K |
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
| Employees | 29 |
| Beta | 1.32 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |